Drug Search Results
More Filters [+]

Seciera

Alternative Names: seciera, otx-101, otx101, otx 101, cequa
Latest Update: 2024-07-01
Latest Update Note: Clinical Trial Update

Product Description

a Novel Nanomicellar Formulation of Cyclosporine A for the Treatment of Keratoconjunctivitis Sicca (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31361655/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Canada | Hong Kong | New Zealand | United States

Approved Indications: Conjunctivitis | Keratoconjunctivitis | Keratoconjunctivitis Sicca

Known Adverse Events: Hyperemia | Pain Unspecified

Company: Sun Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Seciera

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Keratoconjunctivitis Sicca

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20201772

P3

Recruiting

Keratoconjunctivitis Sicca

None

Recent News Events